06:29 AM EST, 01/16/2025 (MT Newswires) -- Incyte ( INCY ) and Syndax Pharmaceuticals ( SNDX ) said Wednesday that the US Food and Drug Administration has approved Niktimvo as a treatment for certain patients with chronic graft-versus-host disease who weigh at least 40 kg.

The company said the drug will be available in two vial sizes -- 9 mg and 22 mg -- and is expected to be available for order in the US starting in early February.

Health care providers can order Niktimvo through a network of specialty distributors.